Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Nemoto R, Miura M, Iwasaki T, Goto H.

Clin Ophthalmol. 2012;6:1633-8. doi: 10.2147/OPTH.S37252. Epub 2012 Oct 8.

2.

INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.

Gomi F, Oshima Y, Mori R, Kano M, Saito M, Yamashita A, Iwata E, Maruko R; Fujisan Study Group.

Retina. 2015 Aug;35(8):1569-76. doi: 10.1097/IAE.0000000000000526.

PMID:
25830698
3.

Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.

Lai TY, Lee GK, Luk FO, Lam DS.

Retina. 2011 Sep;31(8):1581-8. doi: 10.1097/IAE.0b013e31820d3f3f.

PMID:
21610566
4.

One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.

Song MH, Ryu HW, Roh YJ.

Ophthalmologica. 2011;226(3):119-26. doi: 10.1159/000329466. Epub 2011 Jul 13.

PMID:
21757883
5.

Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.

Moon SW, Kim MS, Kim ES, Yu SY, Kwak HW.

Ophthalmologica. 2011;225(3):169-75. doi: 10.1159/000323811. Epub 2011 Jan 27.

PMID:
21273795
6.

One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.

Sakurai M, Baba T, Kitahashi M, Yokouchi H, Kubota-Taniai M, Bikbova G, Oshitari T, Yamamoto S.

Clin Ophthalmol. 2014 Jan 28;8:235-41. doi: 10.2147/OPTH.S54578. eCollection 2014.

7.

Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.

Ricci F, Calabrese A, Regine F, Missiroli F, Ciardella AP.

Retina. 2012 Jul;32(7):1280-8. doi: 10.1097/IAE.0b013e318236e835.

PMID:
22218148
8.

Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy.

Inoue M, Arakawa A, Yamane S, Kadonosono K.

Eye (Lond). 2013 Sep;27(9):1013-20; quiz 1021. doi: 10.1038/eye.2013.179. Epub 2013 Aug 23.

9.
10.

Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.

Sagong M, Lim S, Chang W.

Am J Ophthalmol. 2012 May;153(5):873-882.e2. doi: 10.1016/j.ajo.2011.09.031. Epub 2012 Jan 20.

PMID:
22265146
11.

Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.

Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M, Tsujikawa M.

Am J Ophthalmol. 2010 Jul;150(1):48-54.e1. doi: 10.1016/j.ajo.2010.02.008.

PMID:
20609707
12.

One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients.

Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H, Ariga H.

Am J Ophthalmol. 2012 Jul;154(1):117-124.e1. doi: 10.1016/j.ajo.2011.12.019. Epub 2012 Apr 1.

PMID:
22465366
13.

One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.

Cheng CK, Peng CH, Chang CK, Hu CC, Chen LJ.

Retina. 2011 May;31(5):846-56. doi: 10.1097/IAE.0b013e3181f84fdf.

PMID:
21317837
14.

Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation.

Saito M, Iida T, Kano M.

Retina. 2011 Sep;31(8):1589-97. doi: 10.1097/IAE.0b013e31820f4b21.

PMID:
21654347
15.

Two-year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions.

Tsuchiya D, Yamamoto T, Kawasaki R, Yamashita H.

Retina. 2009 Jul-Aug;29(7):960-5. doi: 10.1097/IAE.0b013e3181a3b7c5.

PMID:
19491727
16.

Two-year results of photodynamic therapy with or without intravitreal ranibizumab for polypoidal choroidal vasculopathy.

Sakurada Y, Iijima H.

J Ocul Pharmacol Ther. 2013 Nov;29(9):832-6. doi: 10.1089/jop.2013.0044. Epub 2013 Aug 20.

PMID:
23962035
17.

Verteporfin photodynamic therapy combined with intravitreal ranibizumab for polypoidal choroidal vasculopathy controversy concerning long-term followup.

Fernández M, Gil M, Gomez-Ulla F, Charlón P.

Case Rep Med. 2012;2012:897097. doi: 10.1155/2012/897097. Epub 2012 Oct 30.

18.

Combined photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy: a 2-year result and systematic review.

Zhao M, Zhou HY, Xu J, Zhang F, Wei WB, Liu NP.

Int J Ophthalmol. 2017 Mar 18;10(3):413-422. doi: 10.18240/ijo.2017.03.14. eCollection 2017.

19.

Treatment Outcomes in Patients with Polypoidal Choroidal Vasculopathy.

Sayman Muslubaş I, Hocaoğlu M, Arf S, Özdemir H, Karaçorlu M.

Turk J Ophthalmol. 2016 Jan;46(1):16-20. Epub 2016 Jan 5.

20.

Comparison of photodynamic therapy to transpupillary thermotherapy for polypoidal choroidal vasculopathy.

Mitamura Y, Kubota-Taniai M, Okada K, Kitahashi M, Baba T, Mizunoya S, Yamamoto S.

Eye (Lond). 2009 Jan;23(1):67-72. Epub 2007 Sep 28.

PMID:
17901880

Supplemental Content

Support Center